Pharmaceuticals dept visits USP India facility in Hyderabad
Hyderabad / Kolkata, Feb 5 (IBNS): Sudhansh Pant, Joint Secretary, Department of Pharmaceuticals (DoP), visited the US Pharmacopeia's (USP) state-of-the-art India facility in Hyderabad.
He toured the facility and met with senior level scientists. The purpose of this visit was to better understand the efforts USP is making in India to create standards for medicines, ensure full safety and quality of medicines and bring to India international standards in drug manufacture.
India’s continued export growth in pharmaceuticals requires that every drug exported meets with the highest quality and safety requirements. USP is uniquely positioned to provide guidelines in this area.
USP develops the reference standards to ensure the quality of Active Pharmaceutical Ingredients (APIs) and is supportive of government initiatives to strengthen and revive the domestic manufacturing of intermediaries and APIs.
The Joint Secretary’s discussion with USP India touched upon various aspects of ensuring the quality of medicines in India and how USP standards could help Indian manufacturers to import their products both to the US and to other countries.
Pant also enquired about the verification program and process and showed interest in the education and training programs conducted by USP. He was very impressed by the state-of-the-art facility and appreciated the quality and safety aspects maintained in the facility.
KV Surendranath, Senior Vice President- International Sites Operations said, “We welcome this opportunity to showcase our technical expertise to the Department of Pharmaceuticals. We see ourselves as partners in India’s efforts to produce safe and high quality medicines that meet all global standards. We hope to continue with future engagements with the DoP on various aspects related to quality of medicines and to address issues of critical importance to patient safety.”
Sudhansh Pant commented that he was very impressed and that the visit was quite enlightening and informative. He noted the commendable work being done at the facility in the field of standards, testing and research and the various collaborations in the interest of the Indian pharmaceutical industry. Mr. Pant hopes that other governments and private institutions will benefit from the presence of USP’s world class facility in Hyderabad.
New Zealand govt imposes 12-day lockdown in Auckland as fresh COVID-19 cases emerge Fri, Aug 14 2020
Bangladesh registers 34 new COVID-19 deaths in 24 hours Fri, Aug 14 2020
Two Chinese people test Covid-19 positive after recovery, raising worries of 'viral reactivation': Report Fri, Aug 14 2020
India conducts record high of nearly 8.5 lakh tests in a single day Fri, Aug 14 2020
Hong Kong reports 48 new confirmed COVID-19 cases, 4,360 in total Fri, Aug 14 2020
India records 1007 COVID-19 deaths in past 24 hours Fri, Aug 14 2020